Multiple regulation pathways and pivotal biological functions of STAT3 in cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yuan, Jie ^a   Zhang, Fei ^a   Niu, Ruifang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ANIMAL; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TUMOR MICROENVIRONMENT;

EID: 84949294600     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17663     Document Type: Article

References (105)

1. Timofeeva, O. A. et al. STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci USA 110, 1267-1272, doi: 10.1073/pnas.1211805110 (2013).
2. Li, J. et al. STAT3 acetylation-induced promoter methylation is associated with downregulation of the ARHI tumor-suppressor gene in ovarian cancer. Oncol Rep 30, 165-170, doi: 10.3892/or.2013.2414 (2013).
3. Lee, H. et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci USA 109, 7765-7769, doi: 10.1073/pnas.1205132109 (2012).
4. Zheng, L. et al. Angiotensin II in atrial structural remodeling: the role of Ang II/JAK/STAT3 signaling pathway. Am J Transl Res 7, 1021-1031 (2015).
5. Smith, G. S., Kumar, A. & Saba, J. D. Sphingosine Phosphate Lyase Regulates Murine Embryonic Stem Cell Proliferation and Pluripotency through an S1P/STAT3 Signaling Pathway. Biomolecules 3, 351-368, doi: 10.3390/biom3030351 (2013).
6. Tonozuka, Y. et al. A GTPase-activating protein binds STAT3 and is required for IL-6-induced STAT3 activation and for differentiation of a leukemic cell line. Blood 104, 3550-3557, doi: 10.1182/blood-2004-03-1066 (2004).
7. Matsuura, A. & Lee, H. H. Crystal structure of GTPase-activating domain from human MgcRacGAP. Biochem Biophys Res Commun 435, 367-372, doi: 10.1016/j.bbrc.2013.04.094 (2013).
8. Raptis, L., Arulanandam, R., Geletu, M. & Turkson, J. The R(h)oads to Stat3: Stat3 activation by the Rho GTPases. Exp Cell Res 317, 1787-1795, doi: 10.1016/j.yexcr.2011.05.008 (2011).
9. Geletu, M. et al. Classical cadherins control survival through the gp130/Stat3 axis. Biochim Biophys Acta 1833, 1947-1959, doi: 10.1016/j.bbamcr.2013.03.014 (2013).
10. Liu, B. S., Cao, Y., Huizinga, T. W., Hafler, D. A. & Toes, R. E. TLR-mediated STAT3 and ERK activation controls IL-10 secretion by human B cells. Eur J Immunol 44, 2121-2129, doi: 10.1002/eji.201344341 (2014).
11. Ying, H. et al. TLR4 mediates MAPK-STAT3 axis activation in bladder epithelial cells. Inflammation 36, 1064-1074, doi: 10.1007/s10753-013-9638-7 (2013).
12. Patel, A. K. & Hackam, A. S. A novel protective role for the innate immunity Toll-Like Receptor 3 (TLR3) in the retina via Stat3. Mol Cell Neurosci 63, 38-48, doi: 10.1016/j.mcn.2014.09.004 (2014).
13. Patel, A. K. & Hackam, A. S. Toll-like receptor 3 (TLR3) protects retinal pigmented epithelium (RPE) cells from oxidative stress through a STAT3-dependent mechanism. Mol Immunol 54, 122-131, doi: 10.1016/j.molimm.2012.11.005 (2013).
14. Tye, H. et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 22, 466-478, doi: 10.1016/j.ccr.2012.08.010 (2012).
15. Ochi, A. et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest 122, 4118-4129, doi: 10.1172/JCI63606 (2012).
16. Kortylewski, M. et al. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonistbased immunotherapy. Cancer Res 69, 2497-2505, doi: 10.1158/0008-5472.CAN-08-3031 (2009).
17. Wild, C. A. et al. Toll-like Receptors in Regulatory T Cells of Patients With Head and Neck Cancer. Arch Otolaryngol Head Neck Surg 136, 1253-1259, doi: 10.1001/archoto.2010.195 (2010).
18. Herrmann, A. et al. TLR9 is critical for glioma stem cell maintenance and targeting. Cancer Res 74, 5218-5228, doi: 10.1158/0008-5472.CAN-14-1151 (2014).
19. Deng, X., Zhao, Y. & Wang, B. miR-519d-mediated downregulation of STAT3 suppresses breast cancer progression. Oncol Rep, doi: 10.3892/or.2015.4160 (2015).
20. Fan, M. Q. et al. Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. J Exp Clin Cancer Res 32, 21, doi: 10.1186/1756-9966-32-21 (2013).
21. Patel, K. et al. MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression. Cancer Lett 347, 54-64, doi: 10.1016/j.canlet.2014.01.020 (2014).
22. Iliopoulos, D., Hirsch, H. A. & Struhl, K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139, 693-706, doi: 10.1016/j.cell.2009.10.014 (2009).
23. Guo, L. et al. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene 32, 5272-5282, doi: 10.1038/onc.2012.573 (2013).
24. Lim, W. A. & Pawson, T. Phosphotyrosine signaling: evolving a new cellular communication system. Cell 142, 661-667, doi: 10.1016/j.cell.2010.08.023 (2010).
25. Cai, T. et al. Glucose-6-phosphate dehydrogenase and NADPH oxidase 4 control STAT3 activity in melanoma cells through a pathway involving reactive oxygen species, c-SRC and SHP2. Am J Cancer Res 5, 1610-1620 (2015).
26. Furcht, C. M. et al. Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells. J Cell Sci 127, 3555-3567, doi: 10.1242/jcs.150862 (2014).
27. Gupta, S. C., Phromnoi, K. & Aggarwal, B. B. Morin inhibits STAT3 tyrosine 705 phosphorylation in tumor cells through activation of protein tyrosine phosphatase SHP1. Biochem Pharmacol 85, 898-912, doi: 10.1016/j.bcp.2012.12.018 (2013).
28. Beales, I. L., Garcia-Morales, C., Ogunwobi, O. O. & Mutungi, G. Adiponectin inhibits leptin-induced oncogenic signalling in oesophageal cancer cells by activation of PTP1B. Mol Cell Endocrinol 382, 150-158, doi: 10.1016/j.mce.2013.08.013 (2014).
29. Dabir, S. et al. PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. Int J Cancer 134, 1045-1054, doi: 10.1002/ijc.28448 (2014).
30. Diao, Y., Wang, X. & Wu, Z. SOCS1, SOCS3, and PIAS1 promote myogenic differentiation by inhibiting the leukemia inhibitory factor-induced JAK1/STAT1/STAT3 pathway. Mol Cell Biol 29, 5084-5093, doi: 10.1128/MCB.00267-09 (2009).
31. Lee, J. H., Kim, C., Sethi, G. & Ahn, K. S. Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel. Oncotarget 6, 6386-6405 (2015).
32. Wilson, H. M. SOCS Proteins in Macrophage Polarization and Function. Front Immunol 5, 357, doi: 10.3389/fimmu.2014.00357 (2014).
33. Fang, S. et al. Platelet factor 4 inhibits IL-17/Stat3 pathway via upregulation of SOCS3 expression in melanoma. Inflammation 37, 1744-1750, doi: 10.1007/s10753-014-9903-4 (2014).
34. Stark, G. R. & Darnell, J. E. Jr. The JAK-STAT pathway at twenty. Immunity 36, 503-514, doi: 10.1016/j.immuni.2012.03.013 (2012).
35. Busch, S., Renaud, S. J., Schleussner, E., Graham, C. H. & Markert, U. R. mTOR mediates human trophoblast invasion through regulation of matrix-remodeling enzymes and is associated with serine phosphorylation of STAT3. Exp Cell Res 315, 1724-1733, doi: 10.1016/j.yexcr.2009.01.026 (2009).
36. Frank, D. A. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 251, 199-210, doi: 10.1016/j. canlet.2006.10.017 (2007).
37. Kojima, H. et al. STAT3 regulates Nemo-like kinase by mediating its interaction with IL-6-stimulated TGFbeta-activated kinase 1 for STAT3 Ser-727 phosphorylation. Proc Natl Acad Sci USA 102, 4524-4529, doi: 10.1073/pnas.0500679102 (2005).
38. Decker, T. & Kovarik, P. Serine phosphorylation of STATs. Oncogene 19, 2628-2637, doi: 10.1038/sj.onc.1203481 (2000).
39. Jain, N., Zhang, T., Kee, W. H., Li, W. & Cao, X. Protein Kinase C Associates with and Phosphorylates Stat3 in an Interleukin-6-dependent Manner. Journal of Biological Chemistry 274, 24392-24400, doi: 10.1074/jbc.274.34.24392 (1999).
40. Lee, H. et al. Persistently Activated Stat3 Maintains Constitutive NF-κ B Activity in Tumors. Cancer Cell 15, 283-293, doi: 10.1016/j.ccr.2009.02.015 (2009).
41. Fan, Y., Mao, R. & Yang, J. NF-kappaB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 4, 176-185, doi: 10.1007/s13238-013-2084-3 (2013).
42. Theiss, A. L. Sphingosine-1-phosphate: Driver of NFkappaB and STAT3 persistent activation in chronic intestinal inflammation and colitis-associated cancer. JAKSTAT 2, e24150, doi: 10.4161/jkst.24150 (2013).
43. He, G. & Karin, M. NF-? B and STAT3-key players in liver inflammation and cancer. Cell Res 21, 159-168, doi: 10.1038/ cr.2010.183 (2010).
44. Nishimoto, A. et al. JAB1 regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cells. Biochem Biophys Res Commun 438, 513-518, doi: 10.1016/j.bbrc.2013.07.105 (2013).
45. Yang, J. et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 65, 939-947 (2005).
46. Timofeeva, O. A. et al. Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. J Biol Chem 287, 14192-14200, doi: 10.1074/jbc.M111.323899 (2012).
47. Shi, S. et al. Drosophila STAT is required for directly maintaining HP1 localization and heterochromatin stability. Nat Cell Biol 10, 489-496, doi: 10.1038/ncb1713 (2008).
48. Shi, S. et al. JAK signaling globally counteracts heterochromatic gene silencing. Nat Genet 38, 1071-1076, doi: 10.1038/ng1860 (2006).
49. Yuan, Z. L., Guan, Y. J., Chatterjee, D. & Chin, Y. E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307, 269-273, doi: 10.1126/science.1105166 (2005).
50. Wang, R., Cherukuri, P. & Luo, J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem 280, 11528-11534, doi: 10.1074/jbc.M413930200 (2005).
51. Ohbayashi, N. et al. LIF-and IL-6-induced acetylation of STAT3 at Lys-685 through PI3K/Akt activation. Biol Pharm Bull 30, 1860-1864 (2007).
52. Jefri, M., Huang, Y. N., Huang, W. C., Tai, C. S. & Chen, W. L. YKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer. BMC Cancer 15, 590, doi: 10.1186/s12885-015-1592-3 (2015).
53. Wang, Y. L. et al. Snail promotes epithelial-mesenchymal transition and invasiveness in human ovarian cancer cells. Int J Clin Exp Med 8, 7388-7393 (2015).
54. Liu, Z. et al. Highmobility group box 1 has a prognostic role and contributes to epithelial mesenchymal transition in human hepatocellular carcinoma. Mol Med Rep, doi: 10.3892/mmr.2015.4182 (2015).
55. Lee, Y., Jung, W. H. & Koo, J. S. Adipocytes can induce epithelial-mesenchymal transition in breast cancer cells. Breast Cancer Res Treat, doi: 10.1007/s10549-015-3550-9 (2015).
56. Lin, Z. et al. S100A4 hypomethylation affects epithelial-mesenchymal transition partially induced by LMP2A in nasopharyngeal carcinoma. Mol Carcinog, doi: 10.1002/mc.22389 (2015).
57. Zhang, C., Guo, F., Xu, G., Ma, J. & Shao, F. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells. Oncol Rep 33, 1872-1882, doi: 10.3892/or.2015.3783 (2015).
58. Kim, M. J., Lim, J., Yang, Y., Lee, M. S. & Lim, J. S. N-myc downstream-regulated gene 2 (NDRG2) suppresses the epithelialmesenchymal transition (EMT) in breast cancer cells via STAT3/Snail signaling. Cancer Lett 354, 33-42, doi: 10.1016/j. canlet.2014.06.023 (2014).
59. Azare, J. et al. Stat3 mediates expression of autotaxin in breast cancer. PLoS One 6, e27851, doi: 10.1371/journal.pone.0027851 (2011).
60. Lee, K., Yeo, S., Sung, C. O. & Kim, S. Twist1 Is a Key Regulator of Cancer-Associated Fibroblasts. Cancer Res, doi: 10.1158/0008-5472.CAN-14-0350 (2014).
61. Fujisaki, K. et al. Cancer-mediated adipose reversion promotes cancer cell migration via IL-6 and MCP-1. Breast Cancer Res Treat 150, 255-263, doi: 10.1007/s10549-015-3318-2 (2015).
62. Fujiwara, Y., Takeya, M. & Komohara, Y. A novel strategy for inducing the antitumor effects of triterpenoid compounds: blocking the protumoral functions of tumor-associated macrophages via STAT3 inhibition. Biomed Res Int 2014, 348539, doi: 10.1155/2014/348539 (2014).
63. Kortylewski, M. et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11, 1314-1321, doi: 10.1038/nm1325 (2005).
64. Wu, L., Du, H., Li, Y., Qu, P. & Yan, C. Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis. Am J Pathol 179, 2131-2141, doi: 10.1016/j. ajpath.2011.06.028 (2011).
65. Diao, J. et al. Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3. Med Oncol 32, 453, doi: 10.1007/s12032-014-0453-2 (2015).
66. Sun, X., Sui, Q., Zhang, C., Tian, Z. & Zhang, J. Targeting blockage of STAT3 in hepatocellular carcinoma cells augments NK cell functions via reverse hepatocellular carcinoma-induced immune suppression. Mol Cancer Ther 12, 2885-2896, doi: 10.1158/1535-7163.MCT-12-1087 (2013).
67. Brown, M. E. et al. Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma. BMC Vet Res 11, 206, doi: 10.1186/s12917-015-0505-7 (2015).
68. Wu, N. et al. Cardamonin induces apoptosis by suppressing STAT3 signaling pathway in glioblastoma stem cells. Tumour Biol, doi: 10.1007/s13277-015-3673-y (2015).
69. Yan, L. I. et al. Expression of signal transducer and activator of transcription 3 and its phosphorylated form is significantly upregulated in patients with papillary thyroid cancer. Exp Ther Med 9, 2195-2201, doi: 10.3892/etm.2015.2409 (2015).
70. Nagaraju, G. P. et al. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1alpha and STAT-3. Angiogenesis 16, 903-917, doi: 10.1007/s10456-013-9364-7 (2013).
71. Onishi, K. & Zandstra, P. W. LIF signaling in stem cells and development. Development 142, 2230-2236, doi: 10.1242/dev.117598 (2015).
72. Ohtsuka, S. & Niwa, H. The differential activation of intracellular signaling pathways confers the permissiveness of embryonic stem cell derivation from different mouse strains. Development 142, 431-437, doi: 10.1242/dev.112375 (2015).
73. Chen, H. et al. Reinforcement of STAT3 activity reprogrammes human embryonic stem cells to naive-like pluripotency. Nat Commun 6, 7095, doi: 10.1038/ncomms8095 (2015).
74. Abubaker, K. et al. Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. Front Oncol 4, doi: 10.3389/ fonc.2014.00075 (2014).
75. Motawi, T. K., El-Boghdady, N. A., El-Sayed, A. M. & Helmy, H. S. Comparative study of the effects of PEGylated interferonalpha2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma. Tumour Biol, doi: 10.1007/ s13277-015-3920-2 (2015).
76. Thakur, R., Trivedi, R., Rastogi, N., Singh, M. & Mishra, D. P. Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep 5, 10194, doi: 10.1038/srep10194 (2015).
77. Ying, J. et al. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells. Int J Oncol 46, 1551-1559, doi: 10.3892/ijo.2015.2851 (2015).
78. Song, J. PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line. Int J Oncol, doi: 10.3892/ijo.2013.1765 (2013).
79. Liu, C.-C. et al. IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulatorsviaDNMT1 upregulation. International Journal of Cancer, n/a-n/a, doi: 10.1002/ijc.29033 (2014).
80. Schroeder, A. et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res 74, 1227-1237, doi: 10.1158/0008-5472.CAN-13-0594 (2014).
81. Chen, C. Y. et al. Bcl3 Bridges LIF-STAT3 to Oct4 Signaling in the Maintenance of Naive Pluripotency. Stem Cells, doi: 10.1002/ stem.2201 (2015).
82. Lin, C. et al. Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/ NF-kB signaling pathways. J Cell Biochem 114, 2061-2070, doi: 10.1002/jcb.24553 (2013).
83. Korkaya, H., Liu, S. & Wicha, M. S. Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory Roots. Clinical Cancer Research 17, 6125-6129, doi: 10.1158/1078-0432.ccr-10-2743 (2011).
84. Garner, J. M. et al. Constitutive Activation of Signal Transducer and Activator of Transcription 3 (STAT3) and Nuclear Factor B Signaling in Glioblastoma Cancer Stem Cells Regulates the Notch Pathway. Journal of Biological Chemistry 288, 26167-26176, doi: 10.1074/jbc.M113.477950 (2013).
85. Conti, L. et al. The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. FASEB J 27, 4731-4744, doi: 10.1096/fj.13-230201 (2013).
86. Jiang, J. et al. MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer. Cancer Lett 356, 962-970, doi: 10.1016/j.canlet.2014.11.007 (2015).
87. Hoque, M. O., Islam, M., Sharma, S. & Teknos, T. N. RhoC Regulates Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma by Overexpressing IL-6 and Phosphorylation of STAT3. PLoS One 9, e88527, doi: 10.1371/journal.pone.0088527 (2014).
88. Yang, J. et al. Tumor-Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/ Stat3/Sox-2 Signaling Pathway. Stem Cells 31, 248-258, doi: 10.1002/stem.1281 (2013).
89. Bayliss, T. J., Smith, J. T., Schuster, M., Dragnev, K. H. & Rigas, J. R. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 11, 1663-1668, doi: 10.1517/14712598.2011.627850 (2011).
90. Tang, Y. J. et al. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro. Genet Mol Res 14, 2450-2460, doi: 10.4238/2015.March.30.3 (2015).
91. Xiao, H. et al. A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells. J Biol Chem 290, 3418-3429, doi: 10.1074/jbc.M114.616748 (2015).
92. Brambilla, L. et al. Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3). Mol Oncol 9, 1194-1206, doi: 10.1016/j.molonc.2015.02.012 (2015).
93. Hayakawa, F. et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J 3, e166, doi: 10.1038/bcj.2013.63 (2013).
94. Kim, M. J. et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett 335, 145-152, doi: 10.1016/j.canlet.2013.02.010 (2013).
95. Wang, Y. X., Cai, H., Jiang, G., Zhou, T. B. & Wu, H. Silibinin inhibits proliferation, induces apoptosis and causes cell cycle arrest in human gastric cancer MGC803 cells via STAT3 pathway inhibition. Asian Pac J Cancer Prev 15, 6791-6798 (2014).
96. Kim, S. et al. Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells. Oncol Rep 32, 2230-2236, doi: 10.3892/or.2014.3450 (2014).
97. Agarwal, C., Tyagi, A., Kaur, M. & Agarwal, R. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 28, 1463-1470, doi: 10.1093/carcin/bgm042 (2007).
98. Bosch-Barrera, J. & Menendez, J. A. Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy. Cancer Treat Rev 41, 540-546, doi: 10.1016/j.ctrv.2015.04.008 (2015).
99. Cao, W. et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinibresistant lung cancer cells. Sci Rep 5, 8477, doi: 10.1038/srep08477 (2015).
100. Sen, M. et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov 2, 694-705, doi: 10.1158/2159-8290.CD-12-0191 (2012).
101. Jing, N. et al. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol Cancer Ther 5, 279-286, doi: 10.1158/1535-7163.mct-05-0302 (2006).
102. Weerasinghe, P. et al. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol 31, 129-136 (2007).
103. Reddy, K. R., Guan, Y., Qin, G., Zhou, Z. & Jing, N. Combined treatment targeting HIF-1alpha and Stat3 is a potent strategy for prostate cancer therapy. Prostate 71, 1796-1809, doi: 10.1002/pros.21397 (2011).
104. Cheng, J. Q. et al. Design and In Vitro Evaluation of Layer by Layer siRNA Nanovectors Targeting Breast Tumor Initiating Cells. PLoS One 9, e91986, doi: 10.1371/journal.pone.0091986 (2014).
105. Stoleriu, M. G. et al. A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3. Eur J Cardiothorac Surg 46, 877-886, doi: 10.1093/ejcts/ezu087 (2014).